Abstract
IBCL-1072: Long-Term Follow-Up From the Rituximab Era Describes a Substantial “One-and-Done” Population After Frontline Treatment for Follicular Lymphoma
Clinical lymphoma, myeloma and leukemia, Vol.26(Supplement 1), pp.S994-S994
08/2026
DOI: 10.1016/S2152-2650(26)02720-5
Abstract
Follicular lymphoma (FL) has historically been considered a chronic, “incurable” cancer requiring intermittent therapy. However, multiple studies have shown that approximately 80% of patients have an overall survival (OS) of 10 years or more. Using the University of Iowa/Mayo Clinic Molecular Epidemiology Resource, we evaluated long-term outcomes in the rituximab era, specifically looking at patients who experienced a sustained benefit from a single line of therapy. We evaluated this prospectively enrolled cohort of patients diagnosed in 2002–2015. The outcomes of interest were OS, eventfree survival (EFS), histologic transformation, and cause of death (lymphoma vs non-lymphoma). We further examined EFS to determine the prevalence of progression/retreatment/transformation in the presence of competing risks of death. A total of 1155 patients with grade 1–3A FL (median follow-up, 14 years) were included from the cohort. In the set of patients who received first-line therapy (n = 752), approximately half did not require a second line of therapy in the first 15 years from diagnosis; these rates were 58% for immunochemotherapy, 41% for rituximab monotherapy, and 59% for those treated with radiation only. In addition, a sizeable subset of patients (34%) who were observed at diagnosis remained treatment-free at 15 years. These findings highlight that a meaningful proportion of patients with FL achieve sustained remission after a single line of therapy, suggesting that a subset may be functionally or essentially “cured.” Further work to identify the clinical and biologic factors determining which patients could be managed with a “one-and-done” approach is needed. Original work presented at the American Society of Hematology Annual Meeting 2025. Modification identifying “one-and-done” population for Lymphoma Research Foundation Scientific Meeting (closed meeting).
Details
- Title: Subtitle
- IBCL-1072: Long-Term Follow-Up From the Rituximab Era Describes a Substantial “One-and-Done” Population After Frontline Treatment for Follicular Lymphoma
- Creators
- Jonathan Day - Mayo Clinic in ArizonaMelissa Larson - Mayo Clinic in ArizonaEric Mou - University of IowaUrshila Durani - Mayo Clinic in ArizonaCarla Casulo - University of RochesterMazie Tsang - Mayo Clinic in ArizonaUmar Farooq - University of IowaPatrizia Mondello - Mayo Clinic in ArizonaJC Villasboas Bisneto - Mayo Clinic in ArizonaCarrie Thompson - Mayo Clinic in ArizonaSergei Syrbu - University of IowaAndrew Feldman - Mayo Clinic in ArizonaChristopher Flowers - The University of Texas MD Anderson Cancer CenterStephen Ansell - Mayo Clinic in ArizonaThomas Witzig - Mayo Clinic in ArizonaThomas Habermann - Mayo Clinic in ArizonaJames Cerhan - Mayo Clinic in ArizonaBrian Link - Mayo Clinic in ArizonaYucai Wang - Mayo Clinic in ArizonaMatthew Maurer - Mayo Clinic in Arizona
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.26(Supplement 1), pp.S994-S994
- DOI
- 10.1016/S2152-2650(26)02720-5
- ISSN
- 2152-2650
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 08/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pathology; Internal Medicine
- Record Identifier
- 9985222743802771
Metrics
1 Record Views